US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines
US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines
美國政府提供7500萬美元支持用於新冠肺炎疫苗的Lipid Systems擴展
- The U.S. government will provide up to $75 million to expand U.K.-listed Croda International Plc's (OTC:COIHF) U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.
- Croda will also invest up to $58 million.
- The investment will be used to establish a new lipid facility in Lamar, Pennsylvania. Construction is expected to start later this year, with the new capacity anticipated in 2025.
- The investment supports the expansion of Croda's portfolio, by creating a third manufacturing site for lipid systems, alongside Croda's existing Alabaster, Alabama, U.S. (Avanti) and Leek, U.K. capabilities.
- The cooperative agreement is a joint award from the Biomedical Advanced Research and Development Authority (BARDA), and an arm of the U.S. Department of defense will join forces for preparedness for future health emergencies.
- Financial Times writes that Pfizer Inc (NYSE:PFE) / BioNTech SE (NASDAQ:BNTX) and Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccines were the first approved jabs to be made with mRNA technology.
- The vaccines rely on bubbles of fat known as lipid nanoparticles to deliver genetic codes that teach the immune system to recognize the virus.
- Lipid systems offer significant potential as the delivery system for many nucleic acid applications, including novel mRNA-based therapeutics, such as flu vaccines and cancer treatments.
- Given the current clinical development pipeline's scale, the lipid systems market is expected to grow significantly over the next ten years.
- Image by Spencer Davis from Pixabay
- 美國政府將提供至多7500萬美元擴大在英國上市的規模克羅達國際公司(場外交易代碼：COIHF)用於新型治療藥物(如信使核糖核酸疫苗)的脂質系統成分的美國製造能力。
- 克羅達還將投資高達5800萬美元。
- 這筆投資將用於在賓夕法尼亞州拉馬爾建立一個新的脂質設施。建設預計將於今年晚些時候開始，新的產能預計在2025年。
- 這筆投資通過創建第三個脂質系統製造基地，支持克羅達擴大產品組合，與克羅達現有的阿拉巴馬州阿拉巴斯市(Avanti)和英國Leek工廠並駕齊驅。
- 這項合作協議是由生物醫學高級研究和發展局(BARDA)聯合頒發的，美國國防部的一個部門將聯合起來，為未來的衞生緊急情況做好準備。
- 英國《金融時報》寫道輝瑞(紐約證券交易所市場代碼：PFE)/BioNTech SE(納斯達克：bntx)和Moderna(納斯達克：信使核糖核酸)新冠肺炎疫苗是第一批被批准使用信使核糖核酸技術製造的疫苗。
- 這些疫苗依靠被稱為脂質納米顆粒的脂肪氣泡來傳遞遺傳密碼，教會免疫系統識別病毒。
- 脂質系統為許多核酸應用提供了巨大的潛力，包括基於信使核糖核酸的新療法，如流感疫苗和癌症治療。
- 鑑於目前臨牀開發管道的規模，脂質系統市場預計在未來十年內將顯著增長。
- 來自Pixabay的斯賓塞·戴維斯攝
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。